HLA-Class II Artificial Antigen Presenting Cells in CD4+ T Cell-Based Immunotherapy

Alexandre Couture; Anthony Garnier; Fabián Docagne; Olivier Boyer; Denis Vivien; BRIGITTE LEMAUFF; Jean‐Baptiste Latouche; Olivier Toutirais

doi:10.3389/fimmu.2019.01081

May 17, 2019Frontiers in ImmunologyOpen Access

HLA-Class II Artificial Antigen Presenting Cells in CD4+ T Cell-Based Immunotherapy

View Full Paper

Ask AI

Bookmark

Share

Key Points

To evaluate the design and application of HLA-class II artificial antigen presenting cells for activating and expanding antigen-specific CD4+ T cells for immunotherapeutic use.
Engineered artificial antigen presenting cell systems displaying human leukocyte antigen (HLA) class II molecules and requisite costimulatory ligands.
Assessed the capacity of HLA-class II engineered platforms to engage CD4+ T cells for targeted cellular expansion.
Engineered HLA-class II artificial antigen presenting cells successfully trigger antigen-specific CD4+ helper T cell activation.
The synthetic platform facilitates robust ex vivo expansion of functional CD4+ T cell populations suitable for adoptive cell transfer.

No abstract yet

We only have this paper's title and publication details.

Read it at the source

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Experimental study demonstrates artificial antigen-presenting cell platforms stimulate therapeutic CD4+ T cells, suggesting viable strategies for scalable adoptive immunotherapy.

Abstract

T cells for immunotherapy.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Couture et al. (2019) studied this question.

synapsesocial.com/papers/69fd2c68dbcb73fbc55d05fc https://doi.org/10.3389/fimmu.2019.01081

View Full Paper

Ask AI

Bookmark

Share

HLA-Class II Artificial Antigen Presenting Cells in CD4+ T Cell-Based Immunotherapy

Key Points

No abstract yet

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

HLA-Class II Artificial Antigen Presenting Cells in CD4+ T Cell-Based Immunotherapy

Key Points

No abstract yet

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading